Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transition period, Austin D. Kim, Executive Vice President, General Counsel and Secretary will be leaving Acadia to pursue other opportunities.

“I’m thrilled to announce these two important additions to the team,” said Steve Davis, Chief Executive Officer. “Jennifer brings strong executive leadership skills with over 20 years of legal, strategy and business experience at emerging, rapidly growing and Fortune 500 life sciences companies. Kimberly’s diverse background in clinical development, regulatory strategy and commercial product expansion will be instrumental in advancing our development pipeline and furthering our efforts to bring DAYBUE to patients worldwide. We look forward to Jennifer and Kimberly’s contributions in support of growing our commercial franchises and advancing new therapies that address significant unmet needs in our patient communities. I would also like to thank Austin for his leadership throughout his tenure at Acadia and wish him the best in his future endeavors.”

Ms. Rhodes most recently served as Executive Vice President and Chief Business Officer from March 2022 and served as General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020 with Angion Biomedica Corp. Ms. Rhodes previously served as General Counsel and Corporate Secretary at Adamas Pharmaceuticals, Inc. from April 2016 until January 2020, during which time she also served as Chief Compliance Officer since August 2016 and Chief Business Officer since January 2017. Prior to that, Ms. Rhodes served as General Counsel at Medivation, Inc. from June 2012 to September 2015, and also served as Corporate Secretary from April 2013 to September 2015 and as Chief Compliance Officer from July 2012 to October 2014. From May 2006 to June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., as well as served as a global product lead for Pfizer Inc.’s primary care medicines. Earlier in her career, Ms. Rhodes served as an attorney with the Wall Street firm Weil, Gotshal & Manges LLP. Ms. Rhodes has a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.

Ms. Manhard most recently served as Executive Vice President, Drug Development at Heron Therapeutics, Inc. from 2016 to 2023. Previously, Ms. Manhard served as Senior Vice President, Regulatory Affairs and Development Operations at Ardea Biosciences Inc. from 2006 to 2016. Earlier in her career, Ms. Manhard served in various roles of increasing responsibility at Exelixis, Inc., Agouron Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, and Bristol Myers Squibb. Ms. Manhard also serves as a member of the board of directors for Shoreline Biosciences, Inc., Inhibrx, Inc., and Toragen, Inc. Ms. Manhard obtained a B.S. in Zoology and B.A. in French from University of Florida, Gainesville.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130798452/en/